Gastric Cancer | Topics

Patients with unresectable or metastatic gastric or gastroesophageal junction cancer that is relapsed/refractory following other approved therapies may benefit from treatment with single-agent CMG901, which was granted fast track designation by the FDA.

Prospective data found higher rates of occult signet ring cell gastric cancer among individuals with no family history of gastric cancer but who carried CDH1 P/LP variants.

Laparoscopy compared with open gastrectomy was found to produce better overall survival outcomes at the 5-year follow-up analysis for patients with advanced gastric cancer.

An analysis presented at 2022 IGCC showed that the level of CD8 + cells in the outer margin of gastric cancer tumors was significantly associated with survival outcomes and could inform prognosis.

Men with MSI-high gastric cancer may have shorter overall survival than women, regardless of treatment modality.

Kohie Shitara, MD, spoke about the use of immunotherapy in the first-line setting for metastatic gastric cancer.

Post-resection survival could be predicted by FAM46C expression in patients with gastric adenocarcinoma.

In a presentation at 2022 IGCC, Ju-Seog Lee, PhD, discussed an analysis that combined tumor classification models to derive new prognostic subgroups in gastric cancer.

Laparoscopic proximal gastrectomy led to less vitamin B12 supplement use than total gastrectomy without negatively impacting survival for upper third early gastric cancer.

Adding pembrolizumab to chemotherapy does not improve outcomes over chemotherapy alone in patients with advanced gastric or gastroesophageal junction adenocarcinoma, according to updated results of the KEYNOTE-062 trial.